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cAMP antagonizes interleukin 2-promoted T-cell cycle progression
at a discrete point in early G1
(restriction point)
KIRK W. JOHNSON*, BRUCE H. DAVISt, AND KENDALL A. SMITH*
Departments of *Medicine and tPathology, Dartmouth Medical School, Hanover, NH 03756
Communicated by H. Sherwood Lawrence, April 6, 1988 (received for review January 5, 1988)
ABSTRACT T lymphocytes are stimulated to proliferate in
an autocrine/paracrine manner by the lymphokine interleukin
2 (IL-2). In seeking further insight into the mechanisms by
which IL-2 induces progression ofT cells through the G, phase
of the cell cycle, studies were performed with agents that
increase cellular adenosine 3',5'-cyclic monophosphate
(cAMP), a well-known inhibitor of lymphocyte growth. The
addition of dibutyryl-cAMP, cholera toxin, forskolin, or 3-
isobutyl-l-methylxanthine to an IL-2-dependent murine T-cell
line evoked a dosw-related suppression of S-phase transition
without affecting cellular viability. Moreover, elevation of
cAMP levels led to an accumulation of uniformly small cells,
suggesting an arrest in early G1. Consistent with these rmdings,
dibutyryl-cAMP inhibited the incorporation of both [3HI-
uridine and [3H]thymidine by IL-2-stimulated, synchronized
normal human T cells. Furthermore, maximal inhibition
occurred during early G1, as indicated by experiments where
the addition of dibutyryl-cAMP was delayed with respect to
IL-2 stimulation. Quantitative flow cytometric analysis ofRNA
and DNA content of IL-2-stimulated cells affirmed that in-
creased cAMP inhibits RNA accumulation and S-phase tran-
sition. In addition, exposure of IL-2-dependent, asynchro-
nously proliferating normal human T cells to dibutyryl-cAMP
resulted in uniform growth arrest in early G1, the point at
which cycling T cells accumulate when they are deprived of
IL-2. These results indicate that increased cAMP inhibits G,
progression stimulated by IL-2 and provide a rationale for the
use of cAMP analogues as pharmacologic probes for the
dissection of molecular events occurring during IL-2 signaling
and T-cell G, transit. They also suggest the possibility of
therapeutic immunosuppression by a combination of agents
that act at different stages of the T-cell cycle.
T-cell proliferation results from antigenic activation of an
autocrine/paracrine system that operates through the lym-
phocytotropic hormone interleukin 2 (IL-2) and its specific,
high-affinity receptor (IL-2R) (reviewed in ref. 1). Two
distinct phases of T-cell growth are evident: one that occurs
by activation of the T-cell antigen-receptor (TCR) complex
and another that results from triggering of the IL-2R (2). The
TCR is responsible for signaling transition from the Go
("resting") state to the G, phase of the cell cycle; this signal
renders the cells "competent" by inducing IL-2R expression
and stimulating IL-2 production (3, 4). Actual progression
through G, into S phase (DNA-synthesis phase) occurs
subsequently, after a certain number of IL-2-receptor inter-
actions have accumulated during the first 4-5 hr of G, (3, 4).
In this way a critical threshold of intracellular signals is
eventually attained, permitting the cells to enter the DNA-
replication phase after a minimum of 10 hr (3-5).
Although it is evident that the triggering of IL-2R is
responsible for T-cell G1 progression, the molecular mecha-
nisms that actually mediate G1 progression are still obscure.
To begin to dissect the events subsequent to IL-2R activa-
tion, we have sought pharmacologic antagonists of T-cell
proliferation. In this regard, increases in adenosine 3',5'-
cyclic monophosphate (cAMP) are known to inhibit the
growth of many cell types, including lymphocytes (reviewed
in refs. 6-11). Studies with cAMP analogues or agents that
elevate cAMP levels have implicated the early events after
TCR stimulation as susceptible to suppression (12-14). In
particular, increased cAMP inhibits inositolphospholipid
turnover, thereby preventing IL-2 production, which nor-
mally occurs within a few hours of triggering of TCRs (15-
21). However, it has remained uncertain whether all of the
inhibition of T-cell proliferation observed after elevation of
cAMP levels can be attributed to an effect on TCR-activated
IL-2 production, or whether IL-2-mediated G1 progression
might also be suppressed. Here we report that a single, early
G1 restriction point results from increased cAMP. Conse-
quently, those cellular changes associated with IL-2-
stimulated G1 progression do not occur, and the cells remain
quiescent, small lymphocytes.
METHODS
Chemicals. N6,02'-Dibutyryl-cAMP (Bt2cAMP), cholera
toxin, and 3-isobutyl-1-methylxanthine were obtained from
Sigma. Forskolin was obtained from Calbiochem. Bt2cAMP
and cholera toxin were solubilized in RPMI 1640 medium to
yield stock concentrations of 20 mM (Bt2cAMP) and 10
,ag/ml (cholera toxin). Isobutylmethylxanthine was i~olubi-
lized in 95% ethanol and forskolin was solubilized in dimethyl
sulfoxide at 500 times the final concentrations desired.
Freshly prepared stock solutions of all chemicals were
diluted to the appropriate final concentration in RPMI 1640
mediumjust before each assay. All control cultures contained
equivalent amounts of vehicle solvent (i.e., ethanol, RPMI,
or dimethyl sulfoxide) as the experimental cultures. The
addition of ethanol and dimethyl sulfoxide to final concen-
trations of 0.2% had no adverse effect on cell proliferation.
Homogeneous recombinant IL-2 was provided by Takeda
Chemical Industries (Osaka, Japan) as a 11.0-mg/ml solution
in ammonium acetate buffer (pH 5.0).
Cell Cultures. Human peripheral blood mononuclear cells
(PBMCs) were isolated by Ficoll/Hypaque discontinuous
gradient centrifugation and cultured in complete medium
consisting of RPMI 1640 (GIBCO) supplemented with 10%
heat-inactivated (560C, 30 min) fetal bovine serum (Sterile
Systems, Logan, UT) and 50 units of penicillin, 50 pug of
gentamicin, and 200 ,ug of L-glutamine (GIBCO) per ml. The
IL-2-dependent murine cytolytic T-lymphocyte line CTLL-2
Abbreviations: Bt2cAMP, N6,02'-dibutyryl-cAMP; IL-2, interleukin
2; IL-2R, IL-2 receptor; TCR, T-cell antigen receptor; PBMC,
peripheral blood mononuclear cell.
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(subclone 15G) was maintained in Iscove's modification of
Dulbecco's modified Eagle's medium as described (22). All
cell proliferation assays were performed in triplicate or
quadruplicate wells of 96-well microtiter plates containing
either 105 PBMCs or 5 x 103 CTLL-2 cells in a total volume
of 0.2 ml of medium. Progression through the G1 and S phases
of the cell cycle was monitored by the incorporation of
[3H]uridine and [3H]thymidine (0.5 ACi per well; 1 ,uCi = 37
kBq; ICN), respectively. In the experiments evaluating
CTLL-2 growth, the cells were cultured with [3H]thymidine
for the last 4 hr of a 24-hr incubation period. The percentage
of viable cells recovered was determined by the Pronase
method (23) as described (24).
Preparation of IL-2R-Positive, Go/G1 T Cells. PBMCs were
enriched for IL-2R-positive, early G1-synchronized T cells by
stimulation of the TCR complex by means of monoclonal
antibodies reactive with the T3 (CD3) component of the
complex (OKT3, 1:10,000 dilution; Ortho Pharmaceuticals).
After a 3-day culture, cells were washed extensively to
remove anti-T3 and any IL-2 produced in situ and then were
recultured in IL-2-free complete medium for 30-48 hr as
indicated. PBMCs cultured in this manner yield a population
of early Gl-synchronized cells consisting of =90% T cells,
equally represented by the T4+ (CD4+) and T8+ (CD8+)
subpopulations (25). Resting cells were then adjusted to 106
per ml and 100-,ul samples were transferred to microtiter
wells. Stimulation of G1 entry and cell-cycle progression of
synchronized cells were achieved by the addition of recom-
binant IL-2 (final concentration, 500 pM); Bt2cAMP was
added either simultaneously or after the times indicated.
Flow Cytometric Analysis of RNA and DNA Content.
Simultaneous measurement of the RNA and DNA content of
individual cells was performed by staining with acridine
orange (Polyscience, Warrington, PA), followed by flow
cytometric analysis (26). Approximately 106 cells were
stained and analyzed within 90 min on an EPICS V flow
cytometer (Coulter). Cells were maintained at 4°C prior to
analysis. Fluorescence was generated with a 300-mW, 488-
nm argon-ion laser beam. Red fluorescence emission was
collected through 488-nm band-pass, 550-nm dichroic, and
610-nm long-pass optical filters. Green fluorescence was
collected through 488-nm band-pass, 550-nm short-pass di-
chroic, and 525-nm band-pass optical filters. Red fluores-
cence intensity is proportional to the RNA content, whereas
the green emission is proportional to the DNA content in each
cell (26). The data are based on a sample size of 50,000 cells,
were collected through 900 and forward angle light-scatter
gates, and were stored by list-mode data acquisition. The
percentages of cells in GlA (early G1) and G1B (late G1) were
determined as described (27) with the PARA 1 and quadstat
software on the MDAD computer system (Coulter).
RESULTS
Increased cAMP Inhibits IL-2-Induced T-Cell Proliferation.
To focus directly on the effects of cAMP on IL-2-induced
T-cell proliferation, a cloned murine cytolytic T-lymphocyte
line (CTLL-2, clone 15G; dependent solely on IL-2 for
growth) was used for the initial experiments. IL-2 was used
at 10 pM, as this concentration is equivalent to both the
equilibrium dissociation constant for IL-2 binding to its
high-affinity receptor (Kd) and the concentration required to
promote a half-maximal proliferative response (EC50) (1).
The membrane-permeant cAMP analogue Bt2cAMP (28)
produced a concentration-dependent suppression of S-phase
transition, as monitored by the incorporation of [3H]thy-
midine during the last 4 hr of a 24-hr culture period (Fig. LA).
Similar results were obtained with cholera toxin (Fig. IB),
which increases cellular cAMP by ADP-ribosylation of the



























FIG. 1. Suppression of IL-2-dependent CTLL-2 cell proliferation
by lt2cAMP (A) and cholera toxin (B). For [3H]thymidine incorpo-
ration (e), results shown represent the mean ± SEM of three
separate experiments (n = 9). Control values were as follows:
without IL-2, 290 ± 91 cpm; 10 pM IL-2, 18,286 ± 543 cpm; 125 pM
IL-2, 39,979 ± 3935 (maximum response). For percent cell viability
(o), the SEM of quadruplicate samples was <10% of the mean in all
cases.
adenylate cyclase system (29). The concentrations effecting
50% inhibition (IC50) were 30 AM (Bt2cAMP) and 0.1 ng/ml
(cholera toxin). Forskolin, a direct activator of the catalytic
unit of adenylate cyclase (30), and isobutylmethylxanthine,
an inhibitor of cyclic nucleotide phosphodiesterase (31), also
suppressed IL-2-dependent CTLL-2 proliferation (IC50 = 50
,M and 5 AM, respectively), further indicating that increased
cAMP is responsible for the abrogation of growth, rather than
a mere nonspecific inhibitory effect by any one agent. The
drug-induced suppression was not reversed by increasing the
concentration of IL-2, even in the presence of only an IC50 of
Bt2cAMP, cholera toxin, or forskolin (data not shown).
The elevation of cAMP levels did not suppress cell prolif-
eration as a consequence of cytotoxicity, as neither Bt2cAMP
nor cholera toxin altered cellular viability at any concentra-
tion (Fig. 1). However, a discernible morphologic effect did
occur after drug exposure: microscopy at the end of the
culture period consistently revealed a uniform population of
small cells, suggestive of arrest in a resting phase (Go or early
G1) of the cell cycle.
Increased cAMP Prevents G1 Progression of IL-2-Stimu-
lated, Synchronized Normal T Cells. Murine CTLL-2 cells
maintained in exponential growth with IL-2 represent a
highly selected, asynchronously proliferating, cloned cell
population. Accordingly, to assess an unselected, synchro-
nized, resting normal T-cell population, human PBMCs were
first stimulated by 3 days of culture with anti-T3 to effect
expression of IL-2Rs. They were then washed free of any
IL-2 produced in situ and allowed to reaccumulate in early G1
during a 2-day culture period in the absence of IL-2. There-
Immunology: Johnson et al.
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after, a saturating concentration of IL-2 (500 pM) was added
and progression through G1 into the S phase was monitored
by [3H]uridine and [3H]thymidine incorporation. The pres-
ence of 250 ,uM Bt2cAMP prevented the IL-2-promoted
gradual and sustained increase in [3H]uridine incorporation
(Fig. 2A), which is normally followed by a similar increase in
[3H]thymidine uptake (Fig. 2B). In contrast, 250 ,uM sodium
butyrate had no effect on IL-2-stimulated cell-cycle progres-
sion, indicating that the inhibition by Bt2cAMP was not due
to possible growth-suppressing activity of released butyric
acid (32).
From findings such as these it appeared that elevation of
cAMP levels suppressed the earliest events essential for
IL-2-promoted G1 progression. Previous studies had re-
vealed that a critical threshold of IL-2-generated signals
accumulates during the first 4-5 hr of IL-2 exposure. Since
this threshold must be surpassed before G1 progression to
DNA replication can occur (3), it follows that if elevated
cAMP levels block early events of IL-2 activation, then
delaying the addition of Bt2cAMP after stimulation of resting
T cells with IL-2 should attenuate the inhibition of cell-cycle
transit. Accordingly, to test this assumption, synchronized,
IL-2R-positive resting T cells were stimulated by the addition
of IL-2 to undergo cell-cycle progression, and Bt2cAMP was
subsequently added at various intervals. The concentration
of Bt2cAMP was chosen to obtain =75% growth inhibition
(IC75, based on Fig. 2). IL-2-mediated G1 progression then
was analyzed by monitoring [3H]uridine incorporation during
the final 2 hr ofthe 32-hr culture period (Fig. 3). The inhibition
of G1 progression by Bt2cAMP was quite dependent on the
interval after IL-2 stimulation at which the drug was added:
maximal inhibition occurred only when Bt2cAMP was added
at the same time as IL-2; the suppression diminished pro-
gressively when the addition of Bt2cAMP was delayed. It is
particularly noteworthy that a delay of 24 hr in the addition
of Bt2cAMP abrogated completely its suppressive effect
(even when [3H]uridine incorporation was measured 10 hr
later, at 32-34 hr of culture). Identical results were obtained
when [H]thymidine incorporation was monitored. These
findings affirm the interpretation that the inhibitory activity
of cAMP occurs early in G1 and obviate nonspecific toxicity
as an explanation for its suppressive effects.
Flow Cytometric Analysis Confilrms an Early G1 Block by
Bt2cAMP. Although these studies consistently pointed to
early G1 as the cell-cycle stage likely influenced by cAMP,
this interpretation necessarily depended upon results ob-
tained with the total cell population studied at intervals
during G1. More convincing data could be provided by flow
cytometric analyses, as they would permit a quantitative
assessment ofRNA and DNA content of individual cells and
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FIG. 3. Time-dependent Bt2cAMP inhibition of IL-2-mediated
T-cell G1 progression. Bt2cAMP (250 ,uM) was added at the times
indicated to early Gl-synchronized, IL-2-activated human T cells.
[3H]Uridine incorporation was monitored for the last 2 hr of a 32-hr
culture period. Values shown represent the mean of two separate
experiments (n = 8) expressed as a percentage of incorporation by
control cells stimulated with 500 pM IL-2, with medium rather than
Bt2cAMP added at the indicated times.
cells moving through G1 to the later phases of the cell cycle.
Accordingly, acridine orange staining followed by flow cy-
tometric analysis was carried out to evaluate changes in RNA
content (red fluorescence) and DNA content (green fluores-
cence) (26) at intervals after the addition of Bt2cAMP [500
,uM (IC90)] to early Gl-synchronized, IL-2-stimulated normal
human T cells. Data representative of three separate exper-
iments are displayed in Fig. 4 and Table 1. Control cells,
activated by anti-T3 for 3 days and then washed and cultured
without IL-2 for 2 days, reaccumulated almost totally in the
early G, (GlA) phase of the cell cycle (Fig. 4A; Table 1). In
contrast, aliquots of these cells reexposed to IL-2 resumed
cell-cycle progression within 24 hr, a change that was even
more prominent after 40 hr of IL-2 exposure (Fig. 4B and
Table 1). On the other hand, as anticipated from the results
obtained by monitoring radiolabeled uridine and thymidine
incorporation, Bt2cAMP prevented the IL-2-mediated pro-
gression through G1, resulting in a cell population with a
fluorescence profile and cell-cycle distribution essentially
identical to that of the resting control cells (Fig. 4C and Table
1). In the absence of IL-2, Bt2cAMP had no additional effect
on the distribution of the cells in the various stages of the cell
cycle (Table 1).
To complement the data obtained with synchronized cells,
asynchronously proliferating IL-2-dependent normal human
FIG. 2. Bt2cAMP inhibition of IL-2-induced
G1 progression-by synchronized human PBMCs.
The incorporation of [3H]uridine (A) or
[3H]thymidine (B) was monitored for 2-hr inter-
vals at the indicated times. *, Control (500 pM
IL-2); o, Bt2cAMP (250 ,uM); *, sodium butyrate
(250 ,uM); A, medium without IL-2. Results are
given as cpm per 10i cells per hr and are the means
oftwo separate experiments (n = 6). The viability
ofBt2cAMP- or sodium butyrate-treated cells was
not significantly different from the IL-2-treated
control cells at any time point (range, 87 ± 2% to
30 io 5'0 92 ± 2%). Standard errors are not indicated for
reasons of clarity but were always slO% of the
hr mean value.
0 10 20 30 40 50
Time, hr
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FIG. 4. Flow cytometric analysis of RNA and DNA content of
IL-2- and Bt2cAMP-treated PBMCs. Acridine orange staining and
dual-parameter analysis for RNA content (red fluorescence) and
DNA content (green fluorescence) was performed with a Coulter
EPICS V flow cytometer. (A) Resting, early GI-synchronized T cells
obtained by IL-2 deprivation as described for Figs. 2 and 3. (B)
Resting T cells stimulated with 500 pM IL-2 for 24 hr. (C) Resting T
cells treated with IL-2 and Bt2cAMP (500 AM) for 24 hr. (D)
Asynchronously proliferating T cells obtained by growth of PBMCs
with anti-T3 for 3 days followed by supplementation with recombi-
nant IL-2 for 2 days. (E) Continually cycling T cells prepared as in
D except for the addition of Bt2cAMP (500 tiM) during the last 30 hr
of culture. Results are representative of three separate experiments.
T cells were examined to define whether single or multiple
cAMP-inhibition points (restriction points) exist during cell-
cycle transition. Based on our observation that IL-2-
dependent CTLL-2 cells become morphologically uniform
and small after exposure to Bt2cAMP or cholera toxin, we
anticipated a discrete growth arrest in early G1. Accordingly,
PBMCs were stimulated with anti-T3 for 3 days, at which
time 500 pM IL-2 was added for 2 days more. The effect of
Bt2cAMP (500 ,uM) was then monitored after an additional 30
hr of culture, as this time interval represents the approximate
mean time for T cells to complete a single growth cycle. The
results (Fig. 4 D and E; Table 2) reveal that addition of
Bt2cAMP results in a concentration-dependent accumulation
of cells in early G1 without arrest at any other phase ofthe cell
cycle. Consequently, the stage at which increased cAMP
arrests growth is identical to that occurring after deprivation
of IL-2 (compare Fig. 4 A and E; Table 2).
DISCUSSION
All of the results support the conclusion that elevation of
cAMP levels antagonizes IL-2-stimulated T-cell G1 progres-
sion, leading to the accumulation of asynchronously prolif-
Table 1. Cell-cycle analysis of IL-2-stimulated resting T cells
Duration, Percentage of cells
Treatment hr GlA G1B S G2 + M
Control 78 19 1 1
IL-2 24 66 24 6 3
IL-2 + Bt2cAMP 24 77 20 2 1
Bt2cAMP 24 80 19 1 1
IL-2 40 35 36 20 9
IL-2 + Bt2cAMP 40 79 18 2 1
Bt2cAMP 40 79 20 1 1
Resting cells were obtained by 30-32 hr of IL-2 deprivation of
cultures activated with anti-T3 for 80-84 hr. Control cells were not
treated further. For treated cultures, recombinant IL-2 was added at
a final concentration of 500 pM and Bt2cAMP was added at a final
concentration of 500 AM. Results represent one of three similar
experiments.
Table 2. Cell-cycle analysis of Bt2cAMP-treated proliferating
T cells
Percentage of cells
Treatment G1A G1B S G2 + M
Control 34 34 24 7
IL-2 washout 71 24 3 1
25 /uM Bt2cAMP 38 33 21 7
500 ,uM Bt2cAMP 65 23 9 3
500 juM Bt2cAMP - IL-2 72 23 4 2
Results represent two experiments. Control PBMCs were cultured
for 3 days with anti-T3 and then maintained in 500 pM IL-2 for the
remainder of the experiment (30 hr). For IL-2 washout, PMBCs were
cultured as above except that IL-2 was washed out before the last 30
hr of culture. For Bt2cAMP treatment, PBMCs were cultured under
control conditions (maintained in 500 pM IL-2) except for the
addition ofBt2cAMP (25 or 500,uM) for the last 30 hr or were cultured
as for "IL-2 washout" except for the addition of Bt2cAMP (500 ttM)
for the last 30 hr.
erating cells at a very early stage of G1. It bears emphasis that
Bt2cAMP, cholera toxin, forskolin, and isobutylmethylxan-
thine all produce similar results, even though these agents
increase cAMP by different mechanisms. Moreover, sodium
butyrate itself is without effect, and none of the agents used
evoke nonspecific cytotoxicity. Accordingly, the phase at
which increased cAMP blocks T-cell proliferation appears to
be the same locus of the T-cell cycle at which IL-2 acts.
This finding is reminiscent of previous work with murine
embryonic 3T3 cells (fibroblasts): a single G1 restriction point
in the 3T3 cell cycle is produced by two diverse situations-
i.e., either serum deprivation or Bt2cAMP administration
(33). Consequently, the observations made with T cells and
those made with 3T3 cells suggest that elevation of cAMP
levels ultimately results in the lack of accumulation, or the
inhibition, of factors critical for G1 progression. In this
regard, it was only possible to examine the effect of increased
cAMP on T-cell growth after a detailed series of experiments
had finally established that IL-2 stimulates T-cell G1 progres-
sion, rather than activation of the TCR as assumed formerly
(1-5). Like the 3T3 cell cycle (34), the earliest phases of the
T-cell cycle can now be divided into the distinct stages of
"competence" and "progression" (3). Thus, it is evident that
TCR activation results in T-cell competence in a manner
closely resembling the acquisition of 3T3 cell competence
stimulated by platelet-derived growth factor and that IL-2
stimulates G1 progression.
It is intriguing that increased cAMP antagonizes both the
TCR complex (15-21) and the IL-2R, since the immediate
biochemical pathways activated and the biologic effects
stimulated by these two receptor systems differ. The TCR
operates through the hydrolysis of phosphotidylinositol and
results in the transcriptional activation of specific genes
including c-fos, c-myc, and genes encoding lymphokines such
as IL-2 and the IL-2R (reviewed in ref. 35). By comparison,
the immediate biochemical events following IL-2R triggering
are unknown and do not appear to involve phosphatidylino-
sitol turnover (36). Further, the genes under IL-2 control
seem to be distinct from those under TCR control and have
only recently begun to be identified (5). However, if a
common mechanism can be found to be responsible for the
cAMP inhibition of both of these receptor systems, the
information gained could contribute to our understanding of
the molecular reactants in the respective activation path-
ways.
Detailed studies with 3T3 cells have shown that serum-
derived epidermal growth factor and insulin-like growth
factor I are necessary to promote movement through the first
half of G1 (37-40). Furthermore, elevation of cAMP blocks
3T3 cell-cycle progression exactly at the midpoint of G1 (38).
Immunology: Johnson et al.
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By comparison, IL-2 is the only G1-progression stimulus for
T cells, and no additional nutrients or hormonal components
supplied by serum are necessary for IL-2-mediated T-cell G1
progression (41). Therefore, it is of interest that cAMP blocks
T cells at the earliest stage of G1, precisely the point at which
IL-2 acts. Whether this difference in the localization of the
cAMP effect on G1 in 3T3 cells and T cells is important must
await information regarding the structure of the p75 a chain
of the IL-2R, since this chain is responsible for IL-2 signal
transduction (42).
Whatever the nature of the signals triggered by IL-2, the
results of the present experiments indicate that they may
never even be initiated when cAMP is increased. Since the
effects of cAMP are mediated by cAMP-dependent protein
kinase (43-47), a phosphorylation event may alter signal
transduction by the IL-2R. This could occur as a conse-
quence of phosphorylation of the IL-2R itself or of the
molecules activated by the receptor or, alternatively, as the
result of a regulatory event affecting the expression of the
genes that are specifically activated by IL-2. For example,
the interaction of IL-2 with its receptor stimulates the
expression of transferrin receptors (48), which facilitate the
cellular uptake of iron, a cofactor necessary for optimal
synthesis of nucleotides necessary for DNA replication (49).
cAMP has been reported to inhibit expression of transferrin
receptors (16), a result that is now understandable, given that
increased cAMP blocks IL-2 stimulation at a very early stage,
well before transferrin receptors are expressed.
Regardless of the precise mechanisms whereby cAMP
produces its effects, the present observations indicate that it
is possible to antagonize IL-2-promoted T-cell immune re-
sponses by using agents that increase cAMP. By comparison,
the two immunosuppressive drugs most commonly used,
glucocorticoids and cyclosporine, function exclusively by
inhibiting the production of IL-2 (5). Inasmuch as increased
cAMP blocks both IL-2 production and IL-2 activity, it
should be possible to potentiate the effects of glucocorticoids
and cyclosporine by adding cAMP-active agents to the
present immunosuppressive regimens. It should likewise be
feasible to decrease the dose of the potentially toxic gluco-
corticoids and cyclosporine by using them in conjunction
with agents that increase cAMP. In this regard, it is note-
worthy that cholera toxin and prostaglandins E1 and E2,
agents known to elevate levels of cAMP, have already been
shown to be effective immunosuppressants (50-52).
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